Figure 3 Comparing the antipermeability effect of native and thawed bevacizumab after freezing at −20°C for 5 days reveals that this procedure leads to a moderate, though not significant, reduction of the antipermeability effect (p = 0.14). Vascular endothelial growth factor (VEGF)‐induced permeability is not inhibited significantly, as shown for the standard bevacizumab (p = 0.3). This should be kept in mind when aliquots of bevacizumab are frozen and thawed before using for the intravitreal injection. Standard bevacizumab leads to a significant reduction in permeability (p = 0.01). SDs are shown.